{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:44:49Z","timestamp":1787985889218,"version":"build-2784847793"},"reference-count":0,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":1095,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Gastroenterology and Hepatology"],"published-print":{"date-parts":[[1997,1]]},"abstract":"<jats:p>Cisapride                             is a substituted benzamide with gastrointestinal prokinetic                             effects presumed to be due to the enhancement of the                             physiological release of acetylcholine at the myenteric                             plexus. In a multicentre study, 189 patients with nonulcer                             dyspepsia (NUD) received single\u2010blind placebo treatment                             for two weeks. A total of 123 patients with no or minimal                             response to placebo and epigastric pain of at least                             moderate severity and frequency were randomly assigned                             to one of three parallel double\u2010blind treatments for                             six weeks: cisapride 10 mg tid, cisapride 20 mg tid                             or placebo. The severity and frequency of individual                             symptoms (epigastric pain, heartburn, nausea, vomiting,                             anorexia, postprandial discomfort, regurgitation, lower                             abdominal pain, bloating and constipation) were assessed                             on a four\u2010 and five\u2010point categorical scale, respectively,                             by the investigator at three on\u2010treatment visits and                             by patients in a daily diary. Analysis of investigator                             and patient assessments for differences in symptom severity                             <jats:bold>x<\/jats:bold> frequency composite scores among the three treatment                             groups showed no statistically significant differences                             for individual symptoms or symptom clusters. As assessed                             by the investigator, and compared with baseline, cisapride                             20 mg tid significantly (P&lt;0.05) improved epigastric                             pain, bloating and early satiety as well as improved                             the total symptom cluster. Investigator evaluation of                             the five most severe and frequent symptoms for each                             patient showed statistically significant improvement                             in each treatment group. For patient diary assessments,                             statistically significant within\u2010treatment improvement                             of the total symptom cluster, the five most severe symptoms                             cluster, bloating and early satiety was observed for                             both cisapride 20 mg and placebo, whereas epigastric                             pain significantly (P&lt;0.05) improved in all three treatment                             groups. Investigator evaluation of global response (good                             + excellent) rate at the end of the six\u2010week treatment                             period was 38% for cisapride 20 mg, 47% for cisapride                             10 mg and 33% for placebo. No statistically significant                             difference in this parameter among treatments was noted.                             Cisapride was well tolerated at both doses with a side                             effect profile comparable with that of placebo. It is                             concluded that, in this double\u2010blind multicentre study                             with a single\u2010blind two\u2010week placebo run\u2010in phase, cisapride                             10 mg tid and 20 mg tid were not effective compared                             with placebo in improving symptoms in NUD patients.                             This study re\u2010emphasizes the good prognosis of patients                             with NUD, with 14% of patients improving in the two\u2010week                             placebo run\u2010in phase and a further 33% improving in                             the next six weeks while on placebo. Within\u2010treatment                             analysis of investigator assessments showed improvement                             for cisapride 20 mg tid suggesting a trend for efficacy                             at this dose.<\/jats:p>","DOI":"10.1155\/1997\/314839","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T21:20:08Z","timestamp":1459459208000},"page":"127-134","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["A Double\u2010Blind Randomized Study of Cisapride in the Treatment of Nonulcer Dyspepsia"],"prefix":"10.1155","volume":"11","author":[{"given":"MC","family":"Champion","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KL","family":"MacCannell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ABR","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Tanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Eberhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SN","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Archambault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"For The Canadian Cisapride Nud Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[1997,5]]},"container-title":["Canadian Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjgh\/1997\/314839.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/1997\/314839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T11:05:06Z","timestamp":1722337506000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/1997\/314839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,1]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1997,1]]}},"alternative-id":["10.1155\/1997\/314839"],"URL":"https:\/\/doi.org\/10.1155\/1997\/314839","archive":["Portico"],"relation":{},"ISSN":["2291-2789","2291-2797"],"issn-type":[{"value":"2291-2789","type":"print"},{"value":"2291-2797","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,1]]},"assertion":[{"value":"1996-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1996-07-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1997-05-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}